S3V Vascular Technologies Limited
₹545▲22.47%(100.00)
About the company
S3V Vascular Technologies Limited is an Indian medical device company established in 2011 and headquartered in Mysore, Karnataka. The company specializes in developing and manufacturing innovative cardiovascular and neurovascular medical devices that support minimally invasive procedures. With a strong focus on improving patient outcomes and making advanced healthcare technologies more accessible, S3V is playing an important role in strengthening India's medical device ecosystem.
The company's product portfolio includes drug-eluting stents, PTCA balloon catheters, and a range of advanced devices designed for cardiovascular and neurovascular interventions. These products are developed to help healthcare professionals treat complex conditions such as coronary artery disease, stroke, and other vascular disorders with greater precision and efficiency. By offering high-quality, cost-effective solutions, S3V aims to reduce dependence on imported medical devices while meeting the growing demand for advanced treatment options in India.
Fundamentals
Valuation
| Metric | Value |
|---|---|
| 52 week high | ₹565 |
| 52 week low | ₹350 |
| P/B ratio | 6.99 |
| Debt to equity | 0.13 |
| ROE (%) | 0.04% |
| Book value | ₹77.97 |
| Face value | ₹10 |
52 week high
52 week low
P/B ratio
Debt
Equity
ROE (%)
| Metric | Value |
|---|---|
| 52 week high | ₹565 |
| 52 week low | ₹350 |
| P/B ratio | 6.99 |
| Debt | 11.5% of capital |
| Equity | 88.5% of capital |
| ROE (%) | 0.04% |
Registry
| Metric | Value |
|---|---|
| PAN number | AAQCS2303F |
| ISIN number | INE0HGT01012 |
Figures in cr ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 13.5 | 15 | 19 | 21 |
| EBITDA | -0.57 | 2.5 | 3.7 | 5.8 |
| OPM | -4.22 | 16.67 | 19.47 | 27.62 |
| PBT | 0.15 | -3.06 | 0.65 | 2.8 |
| PAT | 0.06 | -3.19 | 0.56 | 2.7 |
| EPS | 0.03 | -1.66 | 0.42 | 2.08 |
Shareholding Pattern
N G Badri Narayan
Kalindhi Narayann
L&T Welfare Company Limited
N G Vijaya Gopal
N G Vishnu Shreyas
Others
| Holder | Percentage |
|---|---|
| N G Badri Narayan | 16.76% |
| Kalindhi Narayann | 8.43% |
| L&T Welfare Company Limited | 7.41% |
| N G Vijaya Gopal | 6.12% |
| N G Vishnu Shreyas | 5.05% |
| Others | 56.23% |
Leadership
Frequently asked questions
Common questions on S3V Vascular Technologies Limited—tap a row to read the answer.
Q.1What are S3V Vascular Technologies Limited unlisted shares?
S3V Vascular Technologies Limited unlisted shares are equity shares of the company that are not listed on any recognized stock exchange. These shares are traded through private, off-market transactions and are typically considered by investors looking for exposure to high-growth companies before a potential public listing.
Q.2How can I buy S3V Vascular Technologies Limited unlisted shares?
To invest in S3V Vascular Technologies Limited unlisted shares, you need a valid Demat account and access to a seller offering the shares. Once the price, quantity, and transaction terms are agreed upon, the payment is completed and the shares are transferred electronically to your Demat account through the depository system.
Q.3Is it legal to invest in S3V Vascular Technologies Limited unlisted shares in India?
Yes. Buying and selling unlisted shares is legal in India when the transaction complies with applicable regulations. The transfer should be carried out through authorized depository participants, and all required documentation should be completed to ensure a secure and valid transaction.
Q.4Do I need a Demat account to hold S3V Vascular Technologies Limited unlisted shares?
Yes. A Demat account is required to receive, hold, and transfer unlisted shares electronically. It provides a secure record of ownership and simplifies future transactions if you decide to sell your investment.
Q.5What is the minimum investment required for S3V Vascular Technologies Limited unlisted shares?
There is no fixed minimum investment amount prescribed by the company. The required investment depends on the prevailing share price, the number of shares available for purchase, and the terms agreed upon between the buyer and seller.
Q.6Is there a lock-in period after purchasing S3V Vascular Technologies Limited unlisted shares?
In most cases, there is no mandatory lock-in period for investors purchasing unlisted shares through private transactions. However, if the company is listed on a stock exchange in the future, certain regulatory lock-in provisions may apply to specific categories of shareholders under applicable SEBI regulations.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

NSE IPO 2026: Dates, Allotment & Listing Details
The much-awaited NSE IPO is set to make a major market debut in September 2026. As per the announced schedule, the IPO will open on 21 September and close on 23 September 2026, followed by share allotment on 24 September and listing on 28 September 2026. With strong investor interest and NSE’s position as one of India’s leading market institutions, the IPO is expected to attract significant attention. Here’s a quick look at the NSE IPO 2026 timeline and important dates investors should know.

Upcoming IPOs in 2026: NSE, Rentomojo, Manipal & Pranav Guide
Four major 2026 IPOs: NSE, Manipal Payment, Rentomojo, Pranav Constructions. For pre-IPO investors, these mark critical transitions from private to public valuations. Conduct due diligence before investing.

Purple Style Labs: From Unlisted Shares to IPO - A Price Journey Worth Noticing
Purple Style Labs is making headlines as it moves from the unlisted market towards its IPO. With its unlisted shares trading around ₹500–₹525 and an IPO price band of ₹546–₹575, the price journey offers an interesting look at how private-market and IPO valuations can differ.

Muthoot FinCorp Unlisted Shares: Q1FY27 Profit Surges to ₹705 Cr | Fundamentals & IPO
Muthoot FinCorp's Q1FY27 profit surged to ₹705.48 crore as the company moves toward a proposed ₹3,000-crore IPO. Here's a look at its financial performance, valuation metrics, asset quality and key fundamentals.

From Debt to Debt-Free: How API Holdings Used Thyrocare to Reshape Its Balance Sheet
API Holdings has repaid ₹1,050 crore of debt by monetising a 9.90% stake in Thyrocare while retaining 51.02% control. Here's how the move reshapes its balance sheet and what it means going forward.

Pre IPO Shares in India: Price, How to Buy & Complete Guide
Learn what Pre IPO Shares are, how their prices are determined, how to buy them in India, and what investors should check before investing in unlisted companies.
